

Zelira Therapeutics Ltd.

09:03 21 Nov 2019

Zelda Therapeutics does distribution deal for Australasia and UK

Zelda Therapeutics Ltd (ASX:ZLD) has signed a distribution agreement to distribute Zelda-branded products in Australasia and the UK.

The agreement is with Health House Holdings Ltd, a UK-based specialist medicinal cannabis company that wholesales and distributes medicinal cannabis products to community and hospital pharmacies.

Products covered by the distribution agreement include the insomnia investigation formulation and also the HOPE® range of medicinal cannabis products.

Zelda is planning to launch these products in global market from early 2020.

Increases market penetration in 2020

Zelda's managing director Dr Richard Hopkins said: "This agreement marks another important milestone for Zelda as it prepares to bring multiple medicinal cannabis products to market in 2020.

"We're delighted to be working with Tony Samios and his team at Health House, which has established itself as the premier independent specialist distribution company.

"We're also excited by their ability to help expand distribution of our products into markets throughout Australasia and the United Kingdom."

Proposed merger with Ilera Therapeutics

Zelda will acquire the HOPE® range of medicinal cannabis products as part of its proposed merger with Ilera Therapeutics.

The products were formulated for symptoms associated with autism spectrum disorder.

The intended merger will create a leading medicinal cannabis company rebranded Zelira Therapeutics.

A key priority for Zelira post-merger will be to launch HOPE® into global markets from early 2020, with the aim of generating revenues in the first half of the year.

Regarding Zelda's insomnia formulation, it is planned to go to market in 2020 pending a positive outcome from its phase II clinical trial for which data is expected in the coming March quarter.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

Price: 0.058

Market Cap: \$50.6 m

1 Year Share Price Graph



Share Information

Code: ZLD

Listing: ASX

52 week	High	Low
	0.091	0.04

Sector: Cannabis

Website: www.zeldatherapeutics.com

Company Synopsis:

Zelira Therapeutics Ltd (ASX:ZLD) is a medicinal cannabis company focused on first-in-class human clinical trials for insomnia, autism and opioid reduction.

action@proactiveinvestors.com.au

investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd. named herein, including the promotion by the Company of Zelira Therapeutics Ltd. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).